Sharemaestro Newsreel

Neurocrine Biosciences Q2 revenue rises 39% to $959 million

Dr Reddy's Laboratories Number of Employees 2026 | Employee Count & Headcount Data

Dr Reddy's Laboratories had approximately 28,123 employees worldwide as of March 2026, representing a 3.0% growth from 2023. The company is actively hiring with 449 job postings in 2026 and its workforce is primarily concentrated in South Asia. The average salary is $16,666 globally, …

Hutchmed returns to revenue growth in first half of 2026

Hutchmed (HCM.US; 0013.HK) reported a slight revenue increase in the first half of 2026, driven by double-digit growth in its oncology and immunology drugs which offset declines in other ventures. While revenue rose by 0.2% to $278.3 million, net income significantly dropped to $15.9 …

Tilray Brands, Inc. (TLRY) director gets 43,104 shares, 62,657 RSUs

Tilray Brands, Inc. director Steven Michael Cohen reported changes in his equity holdings, including the vesting of 43,104 Restricted Stock Units (RSUs) on July 29, 2026, which converted into common shares. Following this, his beneficial common stock ownership increased to 55,542 shares. Additionally, Cohen …

Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda

Keros Therapeutics, Inc. LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of …

Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Posts Q2 Adjusted EPS $2.85 per Share, vs. FactSet Est of $1.66

Neurocrine Biosciences Inc. (NBIX) reported Q2 adjusted earnings per share of $2.85, significantly surpassing the FactSet estimate of $1.66. The company also announced Q2 revenue of $959.0 million, exceeding the FactSet estimate of $891.2 million. The article highlights recent news related to Neurocrine Biosciences, …

Form 4 Biofrontera Inc For: 29 July By Investing.com

This article reports on a Form 4 filing for Biofrontera Inc. related to July 29th. It is a brief announcement without further details, typical of financial news sites reporting on regulatory filings. The article also includes various market data and other news headlines from …

Haleon (NYSE: HLN) updates F-3 and S-8 links in Form 6-K/A

Haleon plc (NYSE: HLN) filed an amended Form 6-K/A to update the reference to its latest shelf registration statement on Form F-3, filed on July 29, 2026. This amendment clarifies that the company's July 30, 2026, half-year results are incorporated by reference into both …

TherapeuticsMD Inc (TXMD) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of TherapeuticsMD Inc (TXMD), noting its current valuation score of 7.89, ranking it 84th out of 155 in the Pharmaceuticals industry. It highlights the company's current P/E ratio of 130.46, which is below its recent high but significantly …

Xeris Biopharma (XERS) Expected to Release Quarterly Earnings on Thursday

Xeris Biopharma (XERS) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 6th. Analysts project earnings of $0.02 per share and approximately $90.1 million in revenue. The company currently holds a "Moderate Buy" consensus rating with an average price …

Amneal projects 2026 revenue of $3.1B-$3.2B while raising capex to about $150M

Earnings Call Insights: Amneal Pharmaceuticals (AMRX) Q2 2026 MANAGEMENT VIEW * "Amneal is in the midst of the most transformative period in our company's history," said (Co-Founder, Co-CEO, President & Director Chirag Patel), adding the company is "growing as one of the America's leading …

Alpha Teknova Inc (TKNO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Alpha Teknova Inc (TKNO), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of July 31, 2026, TKNO has a price momentum score of 4.36 and is trading between …

TherapeuticsMD Inc. stock outperforms competitors despite losses on the day

Despite a daily loss of 1.46%, TherapeuticsMD Inc. (TXMD) stock still outperformed competitors and closed at $2.03. This occurred on a positive trading day where the NASDAQ Composite Index and Dow Jones Industrial Average both saw significant gains. The stock is currently 31.19% below …

Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises

Teva Pharmaceutical Industries reported mixed second-quarter 2026 results, with adjusted earnings missing estimates but revenues slightly beating them. The company's stock rose 9.6% after it raised its 2026 revenue outlook, primarily driven by strong performance from its branded drugs Austedo, Ajovy, and Uzedy, and …

Cronos Group Inc. stock rises Thursday, still underperforms market

Cronos Group Inc. (CRON) shares increased by 1.05% on Thursday, closing at $2.89. Despite this gain, the stock underperformed the broader market, as the NASDAQ Composite Index rose by 2.78% and the Dow Jones Industrial Average increased by 1.19%. This marks the second consecutive …

Aurora Cannabis Inc. stock rises Thursday, outperforms market

Aurora Cannabis Inc. (ACB) saw its stock price increase by 3.66% to $2.83 on Thursday, outperforming the broader market. This rise occurred during a favorable trading session where both the NASDAQ Composite Index and the Dow Jones Industrial Average also posted significant gains. This …

Teva (TEVA) Lifts UZEDY Outlook After Record Sales And New FDA Progress

Teva Pharmaceutical Industries (TEVA) reported record quarterly sales for its drug UZEDY, leading to an increased 2026 revenue outlook for the product. The company also announced new regulatory progress for its olanzapine long-acting injectable and a Tourette syndrome drug candidate, ecopipam. Despite the strong …

(HLN) Movement as an Input in Quant Signal Sets

This article analyzes Haleon Plc American Depositary Shares (HLN), highlighting a strong near-term sentiment that could influence neutral mid and long-term outlooks. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides …

Haleon (NYSE: HLN) lifts H1 2026 dividend and posts half-year results

Haleon plc announced its H1 2026 interim dividend for the year ending December 31, 2026, setting it at 2.4 pence per ordinary share. This signifies a 9% increase from the 2025 interim dividend and is consistent with the company's policy of paying approximately one-third …

BHC Q2 Earnings Beat Estimates on Salix and Solta Growth, '26 View Raised

Bausch Health Companies Inc. BHC reported second-quarter 2026 adjusted earnings of $1.26 per share, up 40% year over year. The figure beat the Zacks Consensus Estimate of 96 cents. Revenues increased 13% year over year to $2.85 billion and surpassed the Zacks Consensus Estimate …

Precision Trading with Hims & Hers Health Inc. Class A (HIMS) Risk Zones

This article from Stock Traders Daily provides a detailed analysis of Hims & Hers Health Inc. Class A (HIMS), highlighting a weak sentiment across all time horizons supporting a short bias. It outlines an exceptional 126.1:1 risk-reward short setup and offers three distinct AI-generated …

Optimi Health Corp. (OPTH)

Optimi Health Corp. (OPTH) Cash From Operations (Quarterly)

Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?

Kiniksa Pharmaceuticals International, plc (KNSA) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company. The upward trend …

Do Harrow’s (HROW) Retina Data Updates Quietly Redefine Its Core Growth Strategy?

B. Riley Adjusts Anika Therapeutics Price Target to $21 From $18, Maintains Buy Rating

B. Riley has increased its price target for Anika Therapeutics (ANIK) to $21 from $18, while reaffirming its Buy rating on the stock. This adjustment reflects a positive outlook on the company, concurrent with Barrington also raising its price target to $21 and maintaining …

Bausch Health stock gains after Q2 2026 beat (BHC:NYSE)

Bausch Health (BHC) reported better-than-expected Q2 financials and raised its full-year outlook, leading to a significant stock gain of over 27% on Thursday. This performance marks one of the company's best intraday rallies in nearly a decade. The Canadian drugmaker announced $2.9 billion in …

Tilray Brands seen creating long-term value through diversified platform, Jefferies says

Jefferies has reiterated a 'Buy' rating for Tilray Brands, despite lowering its price target to $19 due to reduced earnings forecasts. The firm sees long-term value in Tilray's transition into a diversified consumer products company, with strong revenue growth from beverage alcohol, cannabis, distribution, …

Perrigo Company plc (NYSE:PRGO) Receives Average Recommendation of "Hold" from Analysts

Analysts have given Perrigo Company plc (NYSE:PRGO) an average "Hold" recommendation, with an average 12-month price target of $19.33. The company's recent quarterly earnings beat estimates but revenue declined year-over-year. Institutional investors and hedge funds own a significant portion of its stock.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced it will provide a company update and its second-quarter 2026 financial results after the market closes on Tuesday, August 4, 2026. A conference call is scheduled for August 4 at 4:30 p.m. Eastern Time to discuss these results …

Earnings call transcript: Amneal tops Q2 2026 estimates, but shares slip

Amneal Pharmaceuticals reported stronger-than-expected Q2 2026 earnings and revenue, with adjusted EPS at $0.30 and revenue at $796.2 million, beating analyst estimates. Despite the strong performance and raised full-year guidance, the stock saw a slight premarket dip, potentially due to its proximity to its …

Liquidia Corp (LQDA) Institutional Confidence

Liquidia Corp (LQDA) has an institutional shareholding score of 7.00, ranking 50 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 73.52%, showing a quarter-over-quarter increase of 0.02%. Farallon Capital Management, L.L.C. is a significant institutional shareholder, holding 8.66 million …

Is is time to sell Aurora Cannabis (TSX:ACB)?

Roth Capital Partners analyst Bill Kirk reiterated a "Neutral" rating on Aurora Cannabis (TSX:ACB) but lowered his price target to $4.00 from $5.00 due to a larger-than-expected drag from Canadian medical cannabis reimbursement changes. While Aurora benefits from its international opportunities and EU-GMP infrastructure, …

Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Amneal Pharmaceuticals (AMRX) reported revenue of $796.2 million, up 9.9% over the same period last year. EPS came in at $0.30, compared to $0.25 in the year-ago quarter. The reported revenue represents a surprise of +3.7% over the …

Aytu Biopharma Inc (AYTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Aytu Biopharma Inc (AYTU) by business segment. As of the latest update on April 6, the company's ADHD portfolio accounts for 87.15% of its revenue, followed by its Pediatric portfolio at 11.14%. EXXUA and "Other" categories contribute …

United Therapeutics CEO Martine Rothblatt sells $4.96 million in stock

Martine A. Rothblatt, CEO of United Therapeutics Corp, sold 9,500 shares worth $4.96 million on July 29, 2026, after exercising stock options. The sale was executed under a pre-arranged 10b5-1 trading plan and occurred after an 86% return in the stock over the past …